<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008332</url>
  </required_header>
  <id_info>
    <org_study_id>TH001</org_study_id>
    <nct_id>NCT01008332</nct_id>
  </id_info>
  <brief_title>Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis</brief_title>
  <official_title>An Escalating, Multiple-dose Study in House Dust Mite Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune HDM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of allergic sensitisation to House Dust Mite (HDM) varies from region to
      region and depends on the regional prevalence of HDM. In the third National Health and
      Nutrition Examination Surveys, 54.3% of the US population had positive test responses to one
      or more allergens, with the prevalence for HDM being 27.5%. Like many other allergens,
      exposure to HDMA in sensitised patients is associated with poorer lung function, greater
      medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms.

      ToleroMune HDM is a novel, synthetic, allergen-derived peptide desensitising vaccine,
      currently being developed for the treatment of Houst Dust Mite allergy.

      The purpose of the present study is to evaluate the safety and tolerability of multiple
      ascending doses of ToleroMune HDM in subjects in subjects with a documented history of
      allergic rhinoconjunctivitis on exposure to house dust mite. The efficacy of ToleroMune HDM
      will also be explored in these subjects using the Late Phase Skin Response, Early Phase Skin
      Response and Conjunctival Provocation Test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled study to evaluate
      the safety and tolerability of escalating multiple doses of ToleroMune HDM in subjects with a
      documented history of allergic rhinoconjunctivitis on exposure to house dust mite. The
      efficacy of ToleroMune HDM will also be explored in these subjects using the LPSR, EPSR, CPT
      and levels of HDM specific IgE. A single centre will be initiated first, with a second centre
      included as a backup, if needed, to enable recruitment numbers to be met.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 8 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of a single visit 1 to 4
      weeks before randomisation.

      Period 2 (Treatment Period) will consist of 4 visits (Visits 3A-3D) four weeks apart (28±2
      days). Subjects who comply with the inclusion/exclusion criteria will be assigned to one of 5
      dose groups. The first dose group will receive 4 administrations of ToleroMune HDM.
      Successive dose groups will increasing doses given as 4 administrations of ToleroMune HDM,
      provided the first administration of the previous dose was safe and well tolerated.

      In Period 3, Post-treatment Challenge will take place 18-22 weeks after the first
      administration in the Treatment Period. Assessments performed will be identical to those at
      the Baseline Challenge. Follow-up will be conducted 3-10 days after PTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple intradermal injections of ToleroMune HDM in HDM allergic subjects with allergic rhinoconjunctivitis</measure>
    <time_frame>18-22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in area of the LPSR 8 hours after intradermal challenge with whole HDM allergen at PTC after ToleroMune HDM injection compared to placebo</measure>
    <time_frame>18-22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in area of the EPSR 15 minutes after intradermal challenge with whole HDM allergen at PTC after ToleroMune HDM injection compared to placebo</measure>
    <time_frame>18-22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in CPT score at PTC after ToleroMune HDM injection compared to placebo</measure>
    <time_frame>18-22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in concentration of HDM specific IgE at PTC after ToleroMune HDM injection compared to placebo</measure>
    <time_frame>18-22 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ToleroMune HDM, subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ToleroMune HDM, subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ToleroMune HDM, subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ToleroMune HDM, subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toleromune HDM, subjects to receive either active or placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toleromune HDM</intervention_name>
    <description>ToleroMune HDM dose 1x4 administrations 4 weeks apart</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator, 1x4 administrations 4 weeks apart</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years

          -  Miniumum 1 year history of rhinoconjunctivitis on exposure to HDM

          -  Positive skin prick test to whole Der p allergen

          -  LPSR to whole Der p allergen 8-10 hours after intradermal injection of greater than
             35mm diameter response

          -  Positive CPT to whole Der p allergen with a score ≥4

        Exclusion Criteria:

          -  Subjects with a history of asthma

          -  Subjects with an FEV1 &lt;80% of predicted

          -  Subjects with a Der f or Der p specific IgE &gt;100 kU/L

          -  Subjects with an acute phase skin response to whole Der p or whole Der f allergen with
             a mean wheal diameter &gt; 50 mm

          -  Subjects who score &gt;1 for redness of conjunctiva or who have any watering or itchiness
             in the eye before administration of the CPT

          -  Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquillizers or
             psychoactive drugs

          -  History of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             malignant, psychiatric, major physical impairment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Hebert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Appliqué en Allergie de Québec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche Appliqué en Allergie de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Rod Hafner, VP R&amp;D</name_title>
    <organization>Circassia Ltd</organization>
  </responsible_party>
  <keyword>House Dust Mite Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Toleromune HDM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

